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Abstract
Purpose
This study investigated the impact of chronic kidney disease on all-causes and cardiovas-
cular mortality in patients with atrial fibrillation treated with digoxin.
Methods
All patients with non-valvular atrial fibrillation and/or atrial flutter as hospitalization diagnosis
from January 1, 1997 to December 31, 2012 were identified in Danish nationwide adminis-
trative registries. Cox proportional hazard model was used to compare the adjusted risk of
all-causes and cardiovascular mortality among patients with and without chronic kidney dis-
ease and among patients with different chronic kidney disease stages within 180 days and
2 years from the first digoxin prescription.
Results
We identified 37,981 patients receiving digoxin; 1884 patients had the diagnosis of chronic
kidney disease. Cox regression analysis showed no statistically significant differences in
all-causes (Hazard Ratio, HR 0.89; 95% confident interval, CI 0.78–1.03) and cardiovascu-
lar mortality (HR 0.88; 95%CI 0.74–1.05) among patients with and without chronic kidney
disease within 180 days of follow-up period. No statistically significant differences was
found using a 2 years follow-up period neither for all causes mortality (HR 0.90; 95%CI
0.79–1.03), nor for cardiovascular mortality (HR 0.87; 95%CI 0.74–1.02). No statistically
significant differences was found comparing patients with and without estimated Glomerular
Filtration Rate <30ml/min/1.73m2 and patients with different stages of chronic kidney
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disease, for all-causes and cardiovascular mortality within 180 days and 2 years from the
first digoxin prescription.
Conclusions
This study suggest no direct effect of chronic kidney disease and chronic kidney disease
stages on all-causes and cardiovascular mortality within both 180 days and 2 years from
the first digoxin prescription in patients treatment-naïve with digoxin for non-valvular atrial
fibrillation.
Introduction
Amain strategy to treat atrial fibrillation is heart rate control. Heart rate control strategy
includes the administration of one or more heart rate controlling agents, including non-dihy-
dropyridine calcium channel antagonists, beta-blockers, and digoxin [1–4]. After the post-
Digoxin Investigation Group trial era [5], digoxin is commonly used worldwide as heart rate
control agent in the treatment of atrial fibrillation [6]. Studies have examined the effect of
digoxin on mortality [7–28], but no single study have directly evaluated the effect of chronic
kidney disease on mortality in patients that receive digoxin for atrial fibrillation. European
Heart Rhythm Associations position paper for heart rate control therapy in patients with
chronic kidney disease [29], endorsed by American and Asian Heart Rhythm Association, rec-
ommend the same treatment to patients with or without kidney disease with appropriate
adjustment of dose according to glomerular filtration rate [29]. Atrial fibrillation and kidney
disease are commonly found in the same patient and prior studies have shown that the pres-
ence of one condition increased the likelihood of finding the other [30–33]. Patients with
chronic kidney disease have generally been excluded from clinical trials, therefore register
based studies are currently the best opportunity to gain further insight [29,33].
The objective of this study was therefore to investigate the impact of chronic kidney disease
on all-causes and cardiovascular mortality when patients with non-valvular atrial fibrillation
initiate treatment with digoxin. The study included the entire Danish population between 1997
and 2012.
Methods
Data sources
All Danish residents are assigned a permanent Civil Personal Register number. This 10-digit
number makes possible to link information from different registers to an individual patient
[34]. Through this identifier, it was possible to link data on prescription fills, hospitalizations
diagnosis, laboratory analysis, surgical procedures, the cause of death and vital status. The
information was collected in the: Danish National Patient Registry [35], Danish Registry of
Medicinal Product Statistics [36], Danish Civil Registration System [37], Clinical laboratory
information system [38] and the National Causes of Death Registry [39]. The original role of
each administrative registry is described elsewhere [35–39].
Study population
All patients with non-valvular atrial fibrillation and/or atrial flutter from January 1, 1997 to
December 31, 2012 were extracted. The diagnosis of atrial fibrillation have been validated in
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the Danish Patient Registry and found to have a verification rate of 99% among hospitalized
patients [40].
From this preliminary population were extracted only digoxin treatment-naïve users who
have initiated pharmacological treatment for non-valvular atrial fibrillation in the period from
January 1, 1997. Patients were excluded if they started digoxin in co-administration with other
antiarrhythmic drugs (including beta-blockers). Treatment initiation date of digoxin was used
as the index date for each patient, as all patients should be diagnosed with non-valvular atrial
fibrillation within the index date.
Study covariates
Age, gender and vital status were obtained at index date. Major comorbidities were evaluated
considering hospitalization diagnosis prior or equal to index date. Hospitalization diagnosis
codes used are shown in S1 Table and was validated in previous studies [41,42]. Pharmacologi-
cal treatment other than digoxin was obtained by claimed prescription up to 180 days before
the index date; for this purpose, Anatomical Therapeutic Classification codes were used and
the relative codes were defined in S2 Table. Evaluation of mean serum potassium and haemo-
globin concentration were obtained based on laboratory sample results up to 180 days before
the index date. The risk of stroke/thromboembolism for all patients was assessed at the index
date according to the CHA2DS2-VASc score (C = Congestive heart failure; H = Hypertension;
A = Age; D = Diabetes; S = Stroke; V = Vascular disease; sc = Sex category), as described else-
where [43].
Outcomes
The study outcomes were all-causes and cardiovascular mortality within 180 days and 2 years
from the index date.
Statistical analysis
Baseline characteristics were compared using the t-tests for continuous variables and χ2 for cat-
egorical variables. Log-rank test was assessed to compare survival curves. All analyses were
based on intention-to-treat and used a statistically significant level of p<0.05 (2-sided). All the
unadjusted analysis were performed using Cox regression analysis with only outcome and
exposure.
In the main analysis, the study population was divided into two cohorts: patients with or
without chronic kidney disease. We classified a patient as having chronic kidney disease if the
patient had a diagnosis of one of the following pathologies classified as International Classifica-
tion of Diseases v.10 codes: N02-08,11,12,14,15.8–16.0,16.2–16.4,16.8,18,19,26, Q61.2,61.3,
61.5,61.9, E10.2,11.2,13.2,14.2 I12.0, M30.0,31.3,31.9,32.15. Patients should be diagnosed with
chronic kidney disease before index date to be included. In the crude analysis, survival proba-
bility was estimated using Kaplan–Meier method for all-causes mortality and cumulative inci-
dence for cardiovascular mortality. Cox proportional hazard model was used to compare the
adjusted risk of all-causes and cardiovascular mortality between the two cohorts. Cox regres-
sion was adjusted for age, sex, year of inclusion, diagnosis of alcohol abuse, myocardial infarc-
tion, diabetes mellitus, heart failure, hypertension, cancer, chronic obstructive pulmonary
disease (COPD), liver disease, syncope, peripheral arterial disease, ventricular arrhythmia,
serum haemoglobin and potassium concentration, stroke or systemic thromboembolism his-
tory, CHA2DS2-VASc score, digoxin dosage and drugs listed in S2 Table. Subjects were fol-
lowed up for 180 days and 2 years from index date and censored at death or at the end of the
follow-up period on December 31, 2012. The assumptions of Cox models were tested, and the
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models were found valid. Five sensitivity analyses were performed. In the first sensitivity analy-
sis, propensity score was used to match patients with chronic kidney disease (exposed) with
four patients without chronic kidney disease (unexposed). This technique matched the exposed
and unexposed by multivariate conditional logistic regression analysis on age, sex, year of
inclusion, diagnosis of myocardial infarction, peripheral arterial disease, alcohol abuse, bleed-
ing history, chronic obstructive pulmonary disease, diabetes mellitus, heart failure, hyperten-
sion, liver disease, stroke or systemic thromboembolism history, CHA2DS2-VASc score,
digoxin dosage and drugs listed in S2 Table. Cox proportional hazard analysis was performed
on the propensity-matched subpopulation to compare the adjusted risk of all-causes and car-
diovascular mortality between the two cohorts.
In the second sensitivity analyses, the subpopulation of patients with concurrent creatinine
measurement within 180 days before index date was selected from the study population.
Applying chronic kidney disease epidemiology collaboration creatinine-based equation [44],
we established the estimated Glomerular Filtration Rate (eGFR). Based on the results of eGFR,
patients were divided into two cohorts, those with eGFR<30 and those with eGFR 30 ml/
min/1.73m2. Each patient with eGFR<30 ml/min/1.73m2 was propensity matched with four
patients with eGFR 30 ml/min/1.73m2 using the method previously described. Cox propor-
tional hazard analysis was performed on the propensity-matched subpopulation to assess the
adjusted risk of all-causes and cardiovascular mortality between the two cohorts. Survival
curves were generated to compare cumulative mortality rate for both cohorts.
In the third sensitivity analysis, the subpopulation of patients that started digoxin therapy
from 1 January 1997 to 31 December 2010 was selected. Considering that the end of follow-up
period was 31 December 2012, this guarantee a potential follow-up period of at least 2 years for
each patient. Three different analysis were performed on this subpopulation generating three
different parts of the third sensitivity analysis. In the part one, we performed the main analysis
using a two-year follow-up period. In parts two and three, we performed the first and second
sensitivity analysis using a two-year follow-up period.
In the fourth sensitivity analysis, we performed the same methods as in the second sensitiv-
ity analysis and part three of third sensitivity analysis using eGFR as continuous predictor and
multi-categorical predictor. In particular, when eGFR was used as multi-categorical predictor,
five groups were generated according to the five stages defined into Kidney Disease Outcome
Quality Initiative clinical practice guidelines [45]. In particular, the five stages considered were:
Stage 5: eGFR< 15; Stage 4: 15 eGFR29; Stage 3: 30 eGFR59; Stage 2: 60 eGFR89;
Stage 1: eGFR90; eGFR measurement unit: ml/min/1.73m2.
In the fifth sensitivity analysis, we performed the same methods as in the main analysis
using a narrow definition of chronic kidney disease. A patient was classified as having a chronic
kidney disease if he/she had a diagnosis of one of the following International Classification of
Diseases v.10 codes: N18.3, N18.4, N18.5, N18.6 and N18.9.
Persistence of digoxin treatment was assessed within 180 days and 2 years follow-up period
from index date. Persistence was defined as the proportion of patients in digoxin treatment on
each relative day throughout each of the individual treatment periods starting at index date
until patient death or at the last digoxin prescription date. This could be assessed based on the
same assumptions of the calculations of the daily dosages, as described elsewhere [46]. An
additional analysis was performed using persistence of digoxin treatment as time of exposure
to digoxin to assess the risk of all-causes and cardiovascular mortality among patients with and
without chronic kidney disease within 180 days and 2 years follow-up period. In particular, the
same methods described in the main analysis and in the third sensitivity analysis—part one
were used respectively, however using persistence of digoxin treatment as time of exposure to
digoxin.
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Data management was performed using SAS statistical software (version 9.4, SAS Institute
Inc., Cary, North Carolina) and data analysis was performed using R (version 3.2.2, R Develop-
ment Core Team). Nearest-neighbor propensity score matching was implemented by using the
MatchIt package in the R statistical program.
Compliance with ethical standards
In Denmark, register-based retrospective studies do not require ethical approval. The study
was approved by the Danish Data Protection Agency. Patient records/information was anon-
ymized and de-identified prior to analysis.
Results
Main analysis
We identified 37,981 patients with a diagnosis of atrial fibrillation that initiated digoxin therapy
without simultaneous treatment with other antiarrhythmic drugs. Of these patients, 1884
patients had the diagnosis of chronic kidney disease (Fig 1). Within 180 days from index date,
54.7% of patients were in continuous digoxin treatment (Fig 2). Baseline characteristics of the
patients are presented in Table 1. Patients with chronic kidney disease were younger and had
more comorbidities compared to patients without chronic kidney disease. During the study
period, only few patients had the measurement (4551 patients) of serum haemoglobin concen-
tration 180 days before index date, resulting to have a mean serum haemoglobin concentration
of 7g/dL. This sub-population was investigated to identify the major causes of this clinical con-
dition, discovering that 1137 (24.98%) out of 4551 patients had diagnosis of anaemia (ICD10
codes: D60-D64). Of the 32947 patients with CHA2DS2-VASc score>1, 18201 (55.24%)
patients were on antithrombotic treatment, of which 13028 patients were treated with low-
dose aspirin (39.54%) and 617 (1.87%) on warfarin.
The study population of 37,981 patients was followed up for 10,294 person-year
(median = 82 days; range = 0–180 days), 22,536 (59.3%) patients died within 180 days of fol-
low-up period. Among these, 14,862 (39.1%) patients died for cardiovascular disease. Kaplan-
Meier survival curves differed between the two cohorts for all-causes mortality (p<0.05) (Fig
3A) as like unadjusted Cox regression analysis showed an increased risk for all-causes and car-
diovascular mortality among patients with chronic kidney disease (Table 2). However, Cox
regression analysis adjusted for age, sex, year of inclusion, diagnosis of alcohol abuse, myocar-
dial infarction, diabetes mellitus, heart failure, hypertension, cancer, COPD, liver disease, syn-
cope, peripheral arterial disease, ventricular arrhythmia, serum haemoglobin and potassium
concentration, stroke or systemic thromboembolism history, CHA2DS2-VASc score, digoxin
dosage and drugs listed in S2 Table, revealed no statistically significant differences in all-causes
[Hazard Ratio (HR) 0.89; 95% Confident Interval (CI) 0.78–1.03)] and cardiovascular mortal-
ity (HR 0.88; 95%CI 0.74–1.05) among patients with and without chronic kidney disease within
180 days from index date (Table 2). Several independent predictors for all-causes and cardio-
vascular mortality were identified, as showed in S3 Table. In particular, peripheral arterial dis-
ease was found associated to an increased risk of 17% (HR 1.17; 95%CI 1.04–1.32) for all
causes mortality and 28% for cardiovascular mortality (HR 1.28; 95%CI 1.10–1.48). Heart fail-
ure was associated to an increased risk of 16% (HR 1.16 95%CI 1.07–1.26) for all causes mortal-
ity and 30% for cardiovascular mortality (HR 1.30; 95%CI 1.18–1.44). COPD and cancer was
associated to an increased risk in all-causes mortality (S3 Table). Among administered drugs,
loop diuretic and low-dose aspirin administration were associated to an increased risk of all-
causes and cardiovascular mortality. Loop diuretic shown an increase of 24% in all-causes
mortality (HR 1.24; 95%CI 1.14–1.34) and 26% in cardiovascular mortality (HR 1.26; 95%CI
Digoxin, Atrial Fibrillation and Chronic Kidney Disease
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1.14–1.40). Low dose aspirin showed an increase of 20% in all-causes mortality (HR 1.20; 95%
CI 1.08–1.34) and 15% in cardiovascular mortality (HR 1.15; 95%CI 1.01–1.32). For both all-
causes and cardiovascular mortality, warfarin administration shown no statistically significant
increase in mortality between the two cohorts. Effect modification was found for age and
CHA2DS2-VASc score for all-causes and cardiovascular mortality (p<0.05). In particular,
there was a progressive increase in risk of both all-causes and cardiovascular mortality compar-
ing patients with CHA2DS2-VASc<1 to patients with CHA2DS2-VASc = 1 or greater than
Fig 1. Flowchart. Flowchart of the study population and sensitivity analysis subpopulations.
doi:10.1371/journal.pone.0160337.g001
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one. Intermediate stroke risk (CHA2DS2-VASc score = 1) was associated to an increase in
mortality of 21% for all-causes mortality and 102% for cardiovascular mortality compared to
lower stroke risk. High stroke risk (CHA2DS2-VASc score>1) was associated to an increase in
mortality of 92% for all-causes mortality and 306% for cardiovascular mortality compared to
lower stroke risk. Similarly, for age, there was an increase in risk of both all-causes and cardio-
vascular mortality comparing age quartiles. Higher haemoglobin concentration in the two
models showed a protective effect and effect modification (p<0.05) showing a progressive
reduction in mortality comparing haemoglobin quartile. Lipid-modifying agents, Renin Angio-
tensin System inhibitor, antithrombotic therapy were protective factors for all-causes mortality,
reducing the risk respectively by 21%, 13% and 14% (S3 Table).
Chronic kidney disease vs. no-Chronic kidney disease and eGFR <30 vs
eGFR 30 ml/min/1.73m2 comparison for all-causes and
cardiovascular mortality using propensity-matched subpopulations
In the first sensitivity analysis, a comparison between patients with chronic kidney disease and
patient without the pathology was performed for all-causes and cardiovascular mortality, using
a propensity score matched subpopulation of 9420 patients (S4 Table). The subpopulation was
followed for 2317 person-year (median = 66 days; range = 0–180 days) and 6201 (65.8%)
patients died within 180 days of follow-up period. Among these, 4163 (44.2%) patients died for
cardiovascular disease. Unadjusted Cox regression analysis showed no statistically significant
increase in all-causes and cardiovascular mortality among patients with chronic kidney disease
Fig 2. Persistencemodel. A treatment persistence model, showing the fraction of patients that is in treatment with digoxin on each relative day of
the individual treatments periods.
doi:10.1371/journal.pone.0160337.g002
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Table 1. Demographic characteristics of all patients (N = 37,981) with non-valvular atrial fibrillation and/or atrial flutter as hospitalization diagnosis
from January 1, 1997 to December 31, 2012 identified in Danish nationwide administrative registries and treated with digoxin for these
pathologies.
Variable Level -Nb(%) or Mean (SDc) No CKDa (Nb =
36,097)
CKDa (Nb =
1884)
Total (Nb =
37,981)
p-value
Age in years–mean (SDc) Nb(%) 81.7 (10.6) 81.1 (9.7) 81.7 (10.5) 0.024
Sex (refd. male) Nb(%) 17241 (47.8) 1134 (60.2) 18375 (48.4) < 0.001
Alcohol abuse Nb(%) 1706 (4.7) 114 (6.1) 1820 (4.8) 0.010
Acute myocardial infarction 3762 (10.4) 287 (15.2) 4049 (10.7) < 0.001
Diabetes mellitus Nb(%) 4660 (12.9) 689 (36.6) 5349 (14.1) < 0.001
Arterial embolism and thrombosis Nb(%) 10240 (28.4) 580 (30.8) 10820 (28.5) 0.025
Pulmonary embolism Nb(%) 651 (1.8) 54 (2.9) 705 (1.9) 0.001
Heart failure Nb(%) 13065 (36.2) 1053 (55.9) 14118 (37.2) < 0.001
Hypertension Nb(%) 12898 (35.7) 1115 (59.2) 14013 (36.9) < 0.001
Cancer Nb(%) 7131 (19.8) 446 (23.7) 7577 (19.9) < 0.001
COPDe Nb(%) 7226 (20.0) 521 (27.7) 7747 (20.4) < 0.001
Liver disease Nb(%) 829 (2.3) 89 (4.7) 918 (2.4) < 0.001
Peripheral arterial disease Nb(%) 2837 (7.9) 296 (15.7) 3133 (8.2) < 0.001
Stroke Nb(%) 9017 (25.0) 500 (26.5) 9517 (25.1) 0.135
Syncope Nb(%) 2517 (7.0) 158 (8.4) 2675 (7.0) 0.022
Ventricular arrhythmias Nb(%) 240 (0.7) 16 (0.8) 256 (0.7) 0.418
Serum potassium concentration
(mEq/L)
Mean (SDc) 4.2 (0.5) 4.4 (0.6) 4.2 (0.5) < 0.001
Patient without measurement within 180 days before index
date
31623 (87.6) 1543 (81.9) 33166 (87.3) < 0.001
Serum haemoglobin concentration
(g/dL)
Mean (SDc) 7.8 (1.2) 7.3 (1.1) 7.8 (1.2) < 0.001
Patient without measurement within 180 days before index
date
31864 (88.3) 1566 (83.1) 33430 (88.0) < 0.001
Lipid modifying agents Nb(%) 2102 (5.8) 185 (9.8) 2287 (6.0) < 0.001
Loop diuretic Nb(%) 16493 (45.7) 1269 (67.4) 17762 (46.8) < 0.001
RASif Nb(%) 7635 (21.2) 564 (29.9) 8199 (21.6) < 0.001
Diabetes mellitus medications Nb(%) 3870 (10.7) 504 (26.8) 4374 (11.5) < 0.001
Antithrombotic medications Total 18962 (52.5) 1052 (55.8) 20014 (52.7) 0.005
Low-dose aspirin 13070 (36.2) 744 (39.5) 13814 (36.4) 0.004
Warfarin 713 (2.0) 27 (1.4) 740 (1.9) 0.115
COPDe drugs Nb(%) 4875 (13.5) 264 (14.0) 5139 (13.5) 0.553
NSAIDg Nb(%) 4936 (13.7) 263 (14.0) 5199 (13.7) 0.751
Stroke risk (CHA2DS2-VASchscore)
High stroke risk 31183 (86.4) 1764 (93.6) 32947 (86.7) < 0.001
Intermediate stroke risk 2513 (7.0) 82 (4.4) 2595 (6.8) < 0.001
Low stroke risk 2401 (6.7) 38 (2.0) 2439 (6.4) < 0.001
Digoxin dosage (μg) mean (SDc) 73.7 (44.5) 65.8 (24.6) 73.3 (43.8) < 0.001
a CKD = chronic kidney disease.
b N. = number.
c SD = standard deviation.
d ref. = reference.
e COPD = Chronic Obstructive Pulmonary Disease.
f RASi = Renin Angiotensin System inhibitor.
g NSAID = Non-Steroidal Anti-inﬂammatory Drugs.
h CHA2DS2-VASc score (C = Congestive heart failure; H = Hypertension; A = Age; D = Diabetes; S = Stroke; V = Vascular disease; sc = Sex category).
doi:10.1371/journal.pone.0160337.t001
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(Table 2). Propensity-matched multivariable Cox regression analysis revealed no significant
statistical difference in all-causes (HR 1.04; 95%CI 0.98–1.10) and cardiovascular mortality
(HR 1.00; 95%CI 0.93–1.08) comparing patients with and without chronic kidney disease
(Table 2). In the second sensitivity analysis, a propensity score-matched subpopulation of 2740
patients was used to compare patients with and without eGFR< 30 ml/min/1.73m2 for all-
causes and cardiovascular mortality (S5 Table). The subpopulation was followed up for 614
person-year (median = 56 days; range = 0–180 days) and 1938 (70.8%) patients died within
180 days of follow-up period. Among these, 1284 (46.9%) patients died for cardiovascular dis-
ease. Unadjusted Cox regression analysis showed no statistically significant increase in all-
causes and cardiovascular mortality among patients with chronic kidney disease (Table 2). Pro-
pensity-matched multivariable Cox regression analysis revealed no significant statistical differ-
ence in all-causes (HR 0.97; 95%CI 0.87–1.09) and cardiovascular mortality (HR 1.00; 95%CI
0.87–1.15) comparing patients with and without eGFR<30 ml/min/1.73m2 (Table 2). Kaplan-
Meier survival curves did not differ for all-causes mortality among cohorts for both sensitivity
analyses (Fig 3B and 3C). The effects of each predictor for each sensitivity analysis were shown
in S6 Table.
Chronic kidney disease vs. no-Chronic kidney disease and eGFR <30 vs
eGFR 30 ml/min/1.73m2 comparison for all-causes and
cardiovascular mortality using a 2 years follow-up period
In the first part of the third sensitivity analysis, a comparison among patients with chronic kid-
ney disease and patient without the pathology was performed for all-causes and cardiovascular
Fig 3. Survival curves. (a) Kaplan-Meier curve for all-cause mortality—main analysis–comparison among patients with and without chronic
kidney disease. (b) Kaplan-Meier curve for all-cause mortality—first sensitivity analysis—comparison among patients with and without chronic
kidney disease using a propensity-matched subpopulation. (c) Kaplan-Meier curve for all-cause mortality—second sensitivity analysis—
comparison among patients with and without eGFR <30 ml/min/1.73m2 using a propensity-matched subpopulation. (d) Cumulative incidence for
cardiovascular mortality—main analysis–comparison among patients with and without chronic kidney disease (Chi-square test statistic: 28.263; p-
value < 0.001). (e) Cumulative incidence for cardiovascular mortality—first sensitivity analysis—comparison among patients with and without
chronic kidney disease using a propensity-matched subpopulation. (f) Cumulative incidence for cardiovascular mortality—second sensitivity—
analysis comparison among patients with and without eGFR <30 ml/min/1.73m2 using a propensity-matched subpopulation. Comparison among
survival curves for all-causes was performed using log-rank test and the p-value was shown in the figure.
doi:10.1371/journal.pone.0160337.g003
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Table 2. Summary of the unadjusted and adjusted Hazard Ratio for all-causes and cardiovascular mortality for all analysis.
ALL CAUSES MORTALITY CARDIOVASCULARMORTALITY
Unadjusted Hazard
Ratio (95% CIa)
Adjusted Hazard
Ratio (95% CIa)
Unadjusted Hazard
Ratio (95% CIa)
Adjusted Hazard
Ratio (95% CIa)
MAIN ANALYSIS
CKDb vs no-CKDb 180 days follow-up period 1.26 (1.19–1.33) 0.89 (0.78–1.03) 1.24 (1.16–1.33) 0.88 (0.74–1.05)
FIRST SENSITIVITY
ANALYSIS
CKDb vs no-CKDb 180 days follow-up period
Propensity-match subpopulation
1.06 (0.99–1.13) 1.04 (0.98–1.10) 1.02 (0.95–1.10) 1.00 (0.93–1.08)
SECOND
SENSITIVITY
ANALYSIS
eGFRc 30 vs No-eGFRc 30 ml/min/1.73m2
180 days follow-up period Propensity-match
subpopulation
1.02 (0.89–1.18) 0.97 (0.87–1.09) 0.97 (0.81–1.16) 1.00 (0.87–1.15)
THIRD
SENSITIVITY
ANALYSIS
Part I: CKDb vs no-CKDb 2 years follow-up
period
1.32 (1.26–1.40) 0.90 (0.79–1.03) 1.31 (1.22–1.39) 0.87 (0.74–1.02)
Part II: CKDb vs no-CKDb 2 years follow-up
period Propensity-match subpopulation
1.09 (1.03–1.16) 1.06 (1.00–1.12) 1.04 (0.97–1.11) 1.00 (0.94–1.08)
Part III: eGFRc30 vs No-eGFRc30 ml/min/
1.73m2 2 years follow-up period Propensity-
match subpopulation
1.10 (0.99–1.22) 1.00 (0.90–1.11) 1.13 (0.99–1.28) 1.00 (0.88–1.14)
FOURTH
SENSITIVITY
ANALYSIS
180 days follow-up period
eGFRc (as continuous variable) 1.00 (0.99–1.00) 1.00 (1.00–1.01) 1.00 (0.99–1.00) 1.00 (0.99–1.00)
Stage 4 (refd. Stage 5) 1.14 (0.76–1.25) 1.42 (0.96–2.09) 1.38 (0.98–1.93) 1.29 (0.73–2.27)
Stage 3 (refd. Stage 5) 0.93 (0.73–1.18) 0.91 (0.72–1.16) 1.26 (0.91–1.75) 1.05 (0.75–1.46)
Stage 2 (refd. Stage 5) 0.92 (0.72–1.16) 0.87 (0.68–1.10) 1.01 (0.79–1.52) 1.12 (0.80–1.55)
Stage 1 (refd. Stage 5) 0.97 (0.76–1.25) 0.84 (0.65–1.08) 0.97 (0.56–1.67) 1.10 (0.78–1.55)
2 years follow-up period
eGFRc (as continuous variable) 1.00 (0.99–1.00) 1.00 (1.00–1.01) 1.00 (0.99–1.00) 1.00 (0.99–1.00)
Stage 4 (refd. Stage 5) 1.02 (0.80–1.29) 1.39 (0.96–1.99) 1.41 (1.00–1.94) 1.07 (0.77–1.48)
Stage 3 (refd. Stage 5) 0.91 (0.73–1.15) 0.90 (0.72–1.14) 1.25 (0.92–1.70) 1.08 (0.79–1.47)
Stage 2 (refd. Stage 5) 0.93 (0.74–1.16) 0.84 (0.67–1.05) 1.13 (0.83–1.54) 1.03 (0.75–1.41)
Stage 1 (refd. Stage 5) 1.05 (0.74–1.48) 0.84 (0.66–1.07) 1.08 (0.67–1.74) 1.46 (0.89–2.38)
FIFTH SENSITIVITY
ANALYSIS
180 days follow-up period- CKDb vs no-CKDb
Using narrow deﬁnition of CKDb
1.28 (1.17–1.40) 0.91 (0.75–1.11) 1.26 (1.14–1.40) 0.97 (0.76–1.23)
2 years follow-up period—CKDb vs no-CKDb
Using narrow deﬁnition of CKDb
1.35 (1.22–1.50) 0.91 (0.76–1.10) 1.35 (1.22–1.50) 0.92 (0.73–1.16)
ADDITIONAL
ANALYSIS
180 days follow-up period- CKDb vs no-CKDb
Using digoxin treatmentpersistence as time of
exposure
1.28 (1.21–1.36) 0.91 (0.79–1.05) 1.27 (1.19–1.37) 0.89 (0.75–1.07)
(Continued)
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mortality in a longer follow-up period of 2 years. A subpopulation of 33,260 patients with 2
years potential follow-up period was used. Adjusted analysis performed showed no statistically
significant effect of chronic kidney disease on all-causes mortality (HR 0.90; 95%CI 0.79–1.03)
and cardiovascular mortality (HR 0.87; 95%CI 0.74–1.02) despite unadjusted Cox regression
analysis showed statistically significant increase in all-causes and cardiovascular mortality
among patients with chronic kidney disease (Table 2). The subpopulation was followed up for
22,063 person-year (median = 242 days; range = 0–730 days) and 25,292 (76.0%) patients died
within 2 years from index date. Among these, 17261 (51.9%) patients died for cardiovascular
disease. Within 2 years from index date, 19.2% of patients were in continuous digoxin treat-
ment (Fig 2). Among predictors, age and CHA2DS2-VASc score had an effect modification
(p<0.05), resulting in an increased risk of all-causes and cardiovascular mortality increasing
the score. In particular, there was an increase in risk of both all-causes and cardiovascular mor-
tality comparing patients with CHA2DS2-VASc<1 to patients with CHA2DS2-VASc = 1 or
greater than one. Patients with high stroke risk (CHA2DS2-VASc score>1) had an increased
risk of 275% for cardiovascular mortality compared to those with low stroke risk (CHA2DS2--
VASc score<1) and 104% for all-causes mortality (S3 Table). Among predictors for all-causes
and cardiovascular mortality, acute myocardial infarction, peripheral arterial disease, COPD
and loop diuretic administration resulted associated to an increased risk of death. Warfarin
administration shown a non-statistical increase in all-causes and cardiovascular mortality.
Instead, low-dose aspirin, showed an increased risk of all-causes mortality of 13% among users
(HR 1.13; 95%CI 1.01–1.25). The effects of all other predictors was shown in S3 Table.
In the second part of the third sensitivity analysis, a comparison among patients with
chronic kidney disease and patient without the pathology was performed for all-causes and car-
diovascular mortality within 2 years from index date, using a propensity score matched sub-
population of 8195 patients (S7 Table). The subpopulation was followed up for 4296 person-
year (median = 59 days; range = 0–730 days) and 6829 (83.3%) patients died within 2 years
from index date. Among these, 4785 (58.4%) patients died for cardiovascular disease. Unad-
justed Cox regression analysis showed statistically significant increase in all-causes mortality
but not for cardiovascular mortality among patients with chronic kidney disease (Table 2).
However, propensity-matched multivariable Cox regression analysis revealed no significant
statistical difference in all-causes (HR 1.06; 95%CI 1.00–1.12) and cardiovascular mortality
(HR 1.00; 95%CI 0.94–1.08) comparing patients with and without chronic kidney disease
(Table 2). The effects of each predictor was shown in S8 Table.
In the third part of the third sensitivity analysis, a comparison between patients with eGFR
<30 and those with eGFR 30 ml/min/1.73m2 was performed for all-causes and cardiovascu-
lar mortality within 2 years from index date, using a propensity score matched subpopulation
Table 2. (Continued)
ALL CAUSES MORTALITY CARDIOVASCULARMORTALITY
Unadjusted Hazard
Ratio (95% CIa)
Adjusted Hazard
Ratio (95% CIa)
Unadjusted Hazard
Ratio (95% CIa)
Adjusted Hazard
Ratio (95% CIa)
2 years follow-up period- CKDb vs no-CKDb
Using digoxin treatmentpersistence as time of
exposure
1.26 (1.19–1.33) 0.96 (0.84–1.10) 1.24 (1.16–1.33) 0.93 (0.79–1.09)
a CI = Conﬁdent interval.
b CKD = Chronic kidney disease.
c eGFR = estimated Glomerular Filtration Rate.
d ref. = reference.
doi:10.1371/journal.pone.0160337.t002
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of 2530 patients (S9 Table). The subpopulation was followed up for 1229 person-year
(median = 52 days; range = 0–730 days) and 2132 (84.3%) patients died within 2 years from
index date. Among these, 1459 (57.7%) patients died for cardiovascular disease. Unadjusted
Cox regression analysis showed no statistically significant increase in all-causes and cardiovas-
cular mortality among patients with chronic kidney disease (Table 2). Propensity-matched
multivariable Cox regression analysis revealed no significant statistical difference in all-causes
(HR 1.00; 95%CI 0.90–1.11) and cardiovascular mortality (HR 1.00; 95%CI 0.88–1.14) between
the two cohorts (Table 2). The effects of each predictor for each sensitivity analysis was shown
in S8 Table.
eGFR as continuous or multi-categorical predictor for all-causes and
cardiovascular mortality within 180 days and 2 years from index date
In the fourth sensitivity analysis, we assessed the risk of all causes and cardiovascular mortality
on a propensity score-matched subpopulation of 2740 patients with creatinine measurement,
using eGFR as continuous predictor and multi-categorical predictor for both 180 days and 2
years follow-up period (S5 Table). Unadjusted Cox regression analysis showed no statistically
significant decrease in all-causes and cardiovascular mortality increasing eGFR for both 180
days and 2 years follow-up period (Table 2). Propensity-matched multivariable Cox regression
analysis revealed no significant statistical decrease in all-causes mortality within 180 days (HR
1.00; 95%CI 1.00–1.01) and 2 years (HR 1.00; 95%CI 1.00–1.01) follow-up period, increasing
eGFR. No statistically significant decrease in the risk cardiovascular mortality was found nei-
ther for 180 days (HR 1.00; 95%CI 0.99–1.00) nor for 2 years (HR 1.00; 95%CI 0.99–1.00) fol-
low-up period, increasing eGFR. Unadjusted Cox regression analysis showed statistically no
significant differences in all-causes and cardiovascular mortality among patients with different
chronic kidney disease stages for both 180 days and 2 years follow-up period (Table 2). No sta-
tistically significant difference in all-causes mortality was found in the adjusted analysis within
180 days (reference group Stage 5; Stage 1 HR 0.84 95%CI 0.65–1.08; Stage 2 HR 0.87 95%CI
0.68–1.10; Stage 3 HR 0.91 95%CI 0.72–1.16; Stage 4 HR 1.42 95%CI 0.96–2.09) follow-up
period. Similar results was found using a 2 years follow-up period (reference group Stage 5;
Stage 1 HR 0.84 95%CI 0.66–1.07; Stage 2 HR 0.84 95%CI 0.67–1.05; Stage 3 HR 0.90 95%CI
0.72–1.14; Stage 4 HR 1.39 95%CI 0.96–1.99). Similarly, no statistically significant difference
was found for cardiovascular mortality within 180 days (reference group Stage 5; Stage 1 HR
1.10 95%CI 0.78–1.55; Stage 2 HR 1.12 95%CI 0.80–1.55; Stage 3 HR 1.05 95%CI 0.75–1.46;
Stage 4 HR 1.29 95%CI 0.73–2.27) follow-up period. Neither using a 2 years follow-up period
(reference group Stage 5; Stage 1 HR 1.46 95%CI 0.89–2.38; Stage 2 HR 1.03 95%CI 0.75–1.41;
Stage 3 HR 1.08 95%CI 0.79–1.47; Stage 4 HR 1.07 95%CI 0.77–1.48).
Comparison for all-causes and cardiovascular mortality within 180 days
and 2 years from index date using a narrow definition of chronic kidney
disease
In the fifth sensitivity analysis, we used a narrow definition of chronic kidney disease. Using
this definition, among 37,981 patients with a diagnosis of atrial fibrillation that initiated
digoxin therapy, 725 patients had the diagnosis of chronic kidney disease compared to 1,884
obtained using a broad definition (S10 Table). Of these patients, 33,260 had a 2-years potential
follow-up period, of which 608 patients had the diagnosis of chronic kidney disease. Unad-
justed Cox regression analysis showed statistically significant increase in all-causes and cardio-
vascular mortality among patients with chronic kidney disease for both 180 days and 2 years
follow-up period (Table 2). However, adjusted Cox regression analysis revealed no significant
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statistical difference in all-causes mortality within 180 days (HR 0.91; 95%CI 0.75–1.11) and 2
years (HR 0.91; 95%CI 0.76–1.10) follow-up period among patients with and without chronic
kidney disease (Table 2). Similarly, no significant statistical difference in cardiovascular mortal-
ity was found within 180 days (HR 0.97; 95%CI 0.76–1.23) and 2 years (HR 0.92; 95%CI 0.73–
1.16) follow-up period (Table 2).
Comparison for all-causes and cardiovascular mortality using the
persistence of digoxin treatment to determine the time of exposure to
digoxin
In the additional analysis, we assessed the risk of all-causes and cardiovascular mortality using
digoxin treatment persistence to determine the time of exposure to digoxin within 180 days
and 2 years follow-up period from the first digoxin prescription. In the cohort of 37,981
patients with a diagnosis of atrial fibrillation that initiated digoxin therapy, within 180 days fol-
low-up period, adjusted Cox regression analysis showed no statistically significant increase in
all-causes (HR 0.91; 95%CI 0.79–1.05) and cardiovascular mortality (HR 0.89; 95%CI 0.75–
1.07) among patients with chronic kidney disease within 180 days follow-up period (Table 2).
Similarly, within a 2 years follow-up period, adjusted Cox regression analysis showed no sta-
tistically significant increase in all-causes (HR 0.96; 95%CI 0.84–1.10) and cardiovascular mor-
tality (HR 0.93; 95%CI 0.79–1.09) among patients with chronic kidney disease within 2 years
follow-up period (Table 2). Unadjusted and adjusted hazard ratio for both all-causes and car-
diovascular mortality within 180 days and 2 years follow-up period were shown in Table 2.
Discussion
To our knowledge, this is the first observational study that directly examined the effect of
chronic kidney disease and its stages on all-causes and cardiovascular mortality among patients
treated with digoxin as unique antiarrhythmic agent for non-valvular atrial fibrillation. To
date, only one study indirectly tried to evaluate the effect of renal function on mortality in a
subpopulation of patients with atrial fibrillation, showing a non-statistically significant interac-
tion term of renal function on mortality in the comparison between digoxin and non-digoxin
users [13]. The current study, instead, directly compared patients with and without chronic
kidney disease, and patients with different stages of chronic kidney disease for all-causes and
cardiovascular mortality, among patients treated with digoxin as unique antiarrhythmic agent
for non-valvular atrial fibrillation. This study design was chosen to avoid the effect of indica-
tion bias in the evaluation of effect of chronic kidney disease on mortality comparing patients
treated with different heart rate control agents. We believe this was necessary because the use
of a specific heart rate control agent was a choice made by the cardiologist based on the clinical
judgement, after an appropriate examination of the patient and it is not a random event. An
unknown number of factors may influence the physician prescription of antiarrhythmic drug
including clinical or prescriber-related factors (recorded or not). Therefore, potential unknown
factors could influence this association comparing patients treated with different antiarrhyth-
mic drugs. This paper, therefore contribute to the current literature both by providing the
results of a direct evaluation of the effect of chronic kidney disease on all-causes and cardiovas-
cular mortality, both by reducing the effect of indication bias in this evaluation, among patients
treated with digoxin as unique antiarrhythmic agent for non-valvular atrial fibrillation. More-
over, our study provide new information to the literature regarding the direct effect of chronic
kidney disease stages in all-causes and cardiovascular mortality among patients treated with
digoxin as unique antiarrhythmic agent for non-valvular atrial fibrillation. Recently, increased
awareness has emerged regarding the effect of the chronic kidney disease stages on clinical
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outcome, especially among cardiologists treating arrhythmic disorders [29]. The main reason
is related to the complexity of the pathological and physiological interactions between the kid-
ney and the heart that could have clinical implications. However, few information are available
on this topic and little is known regarding how different antiarrhythmic drugs could potentially
change these interactions, especially for drugs with narrow therapeutic ranges like digoxin
[47]. Our results shown that no statistically significant difference exist among patients with
eGFR<30 ml/min/1.73m2 and those with eGFR 30 ml/min/1.73m2 or among different
chronic kidney disease stages, in patients treated with digoxin as unique antiarrhythmic agent
for non-valvular atrial fibrillation, within 180 days and 2 years from first digoxin prescription.
Despite not being able to explain any causal relationship for all these findings, we believe
that a plausible explanation could be found in the pathophysiology of chronic kidney disease.
Patients with chronic kidney disease have an excess in cardiovascular mortality because of a
wide range of specific cardiovascular comorbidities. These includes heart failure, stroke, ath-
erosclerosis, anaemia, peripheral artery disease, coronary disease and atrial fibrillation, which
all have shared risk factors with chronic kidney disease [48]. In the current study, all the statis-
tical models were adjusted for all these risk factors for all-causes and cardiovascular mortality
and consequently, the effect of the chronic kidney disease on mortality was evaluated without
the effect of its related comorbidities showing a not statistically significant direct effect on mor-
tality. Reinforcing this hypothesis, in the current study the major impact on mortality was
mainly found to be associated with comorbidities commonly related to chronic kidney disease
[48]. In particular, the presence of heart failure, peripheral arterial disease and anaemia. More-
over, we believe that another possible explanation for our results is that in our study we also
adjusted all the statistical models for digoxin dosage. Digoxin is mainly eliminated through
renal excretion, which is closely related to renal function [49]. Changes in renal function due to
chronic kidney disease could drastically change digoxin serum concentration [50]. It is well
accepted, that digoxin benefit/risk ratio (including mortality) is highly related to its dosage and
consequently to its serum concentration. Digoxin has a narrow therapeutic window and even
small changes in dosage could affect changes in the risk of toxicity. Several pieces of evidence
suggest that increasing digoxin dosage and its related serum concentration does not increase
the clinical effectiveness. Higher dosage provides calcium loading that does not increase thera-
peutic effects, and may cause harm by calcium overload [14,28,51–53]. However, in our model
no direct effect of dosage on all-causes and cardiovascular mortality was observed. A plausible
explanation is that patient with chronic kidney disease were monitored carefully regarding
digoxin posology. Reinforcing this hypothesis, in our study population a lower digoxin dosage
was found among patients with chronic kidney disease.
We believe that another plausible explanation for our results is that all the comparison
among cohorts for all-causes and cardiovascular mortality was performed adjusting for the co-
administrated drug with potential negative effect on mortality in this study population. In fact,
it is interesting to denote that in our study co-administration of loop diuretic and low-dose
aspirin shown an increased risk of all causes and cardiovascular mortality in this study popula-
tion. These results were not surprising considering that both loop diuretics and low-dose aspi-
rin have adverse effects on kidney function, and that loop diuretic could give pharmacokinetic
interactions with digoxin, increasing the risk of adverse clinical outcome [54–63]. However,
the administration of these drugs could also be a proxy for a worst clinical condition. Consider-
ing that safety evaluation in these subpopulations was not an aim of this study, no specific sub-
analysis was performed on these subpopulations. Therefore, more studies are required on this
topic to clarify these associations. Finally, we believe that another possible explanation for our
results is that all the statistical models were adjusted for drugs with positive survival effect in
atrial fibrillation patients, like lipid-modifying agents [64,65]. In particular, is well-know that
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exist a higher risk of atherosclerosis among patients with chronic kidney disease and the lipid-
modifying agents in this subpopulation shown a protective effects on atherosclerosis and car-
diovascular mortality [64,65]. In fact, our results shown that the administration of lipid modi-
fying agents shown instead a protective effect on both all-causes and cardiovascular mortality.
However, considering that safety evaluation in these subpopulations was not an aim of this
study, no specific sub-analysis was performed on these subpopulations. Therefore, more stud-
ies are required on this topic to clarify these associations.
Conclusion
This study suggest no direct effect of chronic kidney disease and also chronic kidney disease
stages on all-causes and cardiovascular mortality within 180 days and 2 years from the first pre-
scription of digoxin among patients treated with digoxin for non-valvular atrial fibrillation.
Despite more studies are necessary to clarify this association, based on our results, whenever
the clinical conditions suggested the use of digoxin as unique antiarrhythmic treatment for
atrial fibrillation, we suggested that the presence of chronic kidney disease should not represent
an obstacle for the prescription of digoxin if a renal excretion-based adjustment of the dosage
is performed. As well as a careful monitoring of the sign and symptoms of digoxin
intoxication.
Limitation
The evaluation of the effect of chronic kidney disease and its stages on all-causes and cardiovas-
cular mortality was performed using an intention to treat approach. This approach could not
account for a possible change in the treatment or covariate during the follow-up period, espe-
cially in the longer follow-up period. A limited amount of patients in our population had bio-
markers measurement (e.g. creatinine, potassium, etc.) within 180 days before index date
potentially due to the data-source used. The LABKA database cover 1.8 million people for a
period of more than 10 years only from the North Denmark region and the Central Denmark
region. Other limitations included a low prevalence of patients with chronic kidney disease
compared to those expected in end-of-life population of patients with atrial fibrillation, short
median observation period of 82 days and low persistence in digoxin treatment. Moreover,
another limitation include a lower prevalence of patients in treatment with warfarin (1.9%) to
those expected in patients with atrial fibrillation. These limitations should be considered when
interpreting the results.
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